Concepedia

Publication | Closed Access

Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma

DOI

38

Citations

38

References

2014

Year

Naoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino, Kentaro Yamanaka, Aya Kita, Masamichi Mori, Sosuke Miyoshi, Sadao Kuromitsu
Clinical Cancer Research

Abstract

These results support a clinical trial of the combination of YM155 with bendamustine and rituximab in relapsed/refractory DLBCL.

References

YearCitations

Page 1